Abstract
BackgroundSince the clinical trial VIGOUR, in which the use of rofecoxib was proved to be connected to a larger number of cardiovascular accidents, an increase in cardiovascular diseases connected to...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
